Quantification of d-mannose in plasma: Development and validation of a reliable and accurate HPLC-MS-MS method

Campi, Beatrice; Codini, Simone; Bisoli, Niccolò; Baldi, Simona; Zucchi, Riccardo; Ferrannini, Ele

doi:10.1016/j.cca.2019.02.024

Cited by 10 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results support previous works reporting higher mannose levels in individuals with glucose perturbations than in those without [20, 21], further extending them by documenting significantly higher levels in patients with previously known DM compared to those with newly detected T2DM. Even though there is no reference range for mannose concentrations, mainly because of different assay methods, our findings in patients with known DM, 98.0 (79.4−120.7) μmol/L, are comparable to the concentrations measured by assays based on mass spectrometry [18,20]. Consistent with previous observations [9,12,20, 21], we noted a positive linear correlation between mannose and glucose concentrations in the total population.…”

Section: Discussionsupporting

confidence: 90%

“…IGT is a state of intermediate glucose intolerance that can only be diagnosed with an OGTT and that has a high prognostic value for future CV events in patients with CAD [ 6 , 24 – 29 ]. The use of HPLC–MS-MS for the assay of plasma mannose not only eliminates the interference of blood glucose, which is present at much higher concentrations, but thanks to its adequate selectivity, reproducibility (relative SD < 10%), accuracy (96–104%), and limited cost, represents a suitable tool for mannose quantification in clinical settings [ 12 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

“…Mannose was assayed by high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC–MS-MS) at the Mass Spectrometry laboratory in Pisa, Italy. In brief, plasma mannose was separated from its epimers, glucose and galactose, by HPLC and LC–MS-MS was then used to quantify its concentrations [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study

Fortin

Ferrannini

Campi

et al. 2022

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

Background Plasma mannose, an emerging novel biomarker of insulin resistance, is associated with both diabetes mellitus and coronary atherosclerosis, but the relationship between mannose concentrations and myocardial infarction (MI) across different glycaemic states remains to be elucidated. The aim of this study was to investigate the independent association between mannose and a first MI in a group of subjects characterized according to their glycaemic state. Methods Fasting plasma mannose concentrations were analysed in 777 patients 6–10 weeks after a first myocardial infarction and in 770 matched controls by means of high-performance liquid chromatography coupled to tandem mass spectrometry. Participants without known diabetes mellitus were categorized by an oral glucose tolerance test (OGTT) as having normal glucose tolerance (NGT, n = 1045), impaired glucose tolerance (IGT, n = 246) or newly detected type 2 diabetes (T2DM, n = 112). The association between mannose and MI was investigated across these glycaemic states by logistic regression. Results Mannose levels increased across the glycaemic states (p < 0.0001) and were significantly associated with a first MI in the whole study population (odds ratio, OR: 2.2; 95% CI 1.4 to − 3.5). Considering the different subgroups separately, the association persisted only in subjects with NGT (adjusted OR: 2.0; 95% CI 1.2–3.6), but not in subgroups with glucose perturbations (adjusted OR: 1.8, 95% CI 0.8–3.7). Conclusions Mannose concentrations increased across worsening levels of glucose perturbations but were independently associated with a first MI only in NGT individuals. Thus, mannose might be a novel, independent risk marker for MI, possibly targeted for the early management of previously unidentified patients at high cardiovascular risk.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study

Fortin

Ferrannini

Campi

et al. 2022

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Plasma mannose concentrations were measured by an HPLC-MS-MS method developed and validated in the Pisa Metabolism laboratory [7].…”

Section: Methodsmentioning

confidence: 99%

Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance

Ferrannini

Andreini

Campi

et al. 2022

International Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Background: High mannose has previously associated with insulin resistance and cardiovascular disease (CVD). Our objective is to establish whether mannose is associated with anatomical evidence of coronary artery disease (CAD). Methods: Plasma mannose concentrations were measured by liquid chromatography/tandem mass spectrometry in a discovery cohort (n = 513) and a validation cohort (n = 221) of carefully phenotyped individuals. In both cohorts CAD was quantitated using state-of-the-art imaging techniques (coronary computed coronary tomography angiography (CCTA), invasive coronary angiography and optical coherence tomography). Information on subsequent CVD events/death was collected. Associations of mannose with angiographic variables and biomarkers were tested using univariate and multivariate regression models. Survival analysis was performed using the Kaplan-Meier estimator. Results: Mannose was related to indices of CAD and features of plaque vulnerability. In the discovery cohort, mannose was a marker of quantity and quality of CCTA-proven CAD and subjects with a mannose level in the top quartile had a significantly higher risk of CVD events/death (p = 3.6e-5). In the validation cohort, mannose was significantly associated with fibrous cap thickness < 65 μm (odds ratio = 1.32 per each 10 μmol/L mannose change [95% confidence interval, 1.05-1.65]) and was an independent predictor of death (hazard ratio for mannose≥vs < 84.6 μmol/L: 4.0(95%CI, 1.4-11.3), p = 0.006). Conclusion:The current data add novel evidence that high mannose is a signature of CAD with a vulnerable plaque phenotype, consistently across measures of severity of vessel involvement and independent of the traditional correlates of CVD, and that it is an independent predictor of incident adverse outcomes.

show abstract

“…Plasma mannose concentrations were measured by liquid chromatography/mass spectrometry (LC-MS-MS); the analytical method has been reported (Campi et al, 2019). In brief, high-performance liquid chromatography (HPLC) was optimized to separate mannose from glucose, which is present at a 100fold higher concentrations in human plasma; LC-MS-MS was then used to quantify mannose concentrations.…”

Section: Plasma Mannose Measurementmentioning

confidence: 99%

Mannose is an insulin-regulated metabolite reflecting whole-body insulin sensitivity in man

et al. 2020

View full text Add to dashboard Cite

Quantification of d-mannose in plasma: Development and validation of a reliable and accurate HPLC-MS-MS method

Cited by 10 publications

References 24 publications

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study

Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance

Mannose is an insulin-regulated metabolite reflecting whole-body insulin sensitivity in man

Contact Info

Product

Resources

About